Post job

Innocore Pharmaceuticals's revenue is $3.0 million.

What is Innocore Pharmaceuticals's revenue?

Innocore Pharmaceuticals's annual revenue is $3.0M. Zippia's data science team found the following key financial metrics about Innocore Pharmaceuticals after extensive research and analysis.
  • Innocore Pharmaceuticals has 30 employees, and the revenue per employee ratio is $100,000.
  • Innocore Pharmaceuticals peak revenue was $3.0M in 2024.

On this page

Peak revenue
$3.0M (2024)
Company peak revenue
Revenue / employee
$100,000
Company revenue / employee

Zippia finds jobs where you're a top candidate and applies on your behalf.

Floating question marks illustration
Peak revenue
$3.0M (2024)
Company peak revenue
Revenue / employee
$100,000
Company revenue / employee

Innocore Pharmaceuticals revenue FAQs

Search for jobs

Zippia gives an in-depth look into the details of Innocore Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Innocore Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Innocore Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Innocore Pharmaceuticals. The data presented on this page does not represent the view of Innocore Pharmaceuticals and its employees or that of Zippia.

Innocore Pharmaceuticals may also be known as or be related to InnoCore Pharmaceuticals and Innocore Pharmaceuticals.